Clinical trial NCT03727022: A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Official title: A Phase 2, 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Two Injections of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Knee Osteoarthritis
Keywords: SM04690
Wnt pathway inhibitor
osteoarthritis
Samumed
Lead sponsor: Biosplice Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2018-11-01
Enrollment: 102
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this phase 2, placebo-controlled, double-blind, parallel group study is to provide an initial evaluation of two intra-articular (IA) injections of SM04690 (each at the dose of 0.07mg per 2mL injection) approximately six months apart into the target knee of moderately to severely symptomatic osteoarthritis (OA) subjects. Subjects who complete this 52-week long study will be eligible to enter the extension phase for an additional 52 weeks of treatment.


Eligibility criteria: Inclusion Criteria:

1. Males and females between 40 and 80 years of age, inclusive, in general good health
2. Ambulatory
3. Diagnosis of femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria at Screening Visit 1 (clinical AND radiographic criteria); OA of the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis)
4. Pain compatible with OA of the knee(s) for at least 26 weeks prior to Screening Visit 1
5. Primary source of pain throughout the body is due to OA in the target knee
6. Daily OA knee pain diary average NRS intensity score ≥ 4 and ≤ 8 in the target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1
7. Pain NRS scores recorded for the target knee on at least 4 out of the 7 days immediately preceding Day 1
8. Daily OA knee pain diary average NRS intensity score \< 4 in the non-target knee on the 11-point (0-10) NRS scale for the 7 days immediately preceding Day 1
9. Pain NRS scores recorded for the non-target knee on at least 4 out of the 7 days immediately preceding Day 1
10. WOMAC pain subscore of 20-40 (out of 50) and WOMAC physical function subscore of 68-136 (out of 170) for the target knee at baseline, regardless of if the subject is on symptomatic oral treatment (baseline questionnaire completed during the screening period prior to randomization)
11. Widespread Pain Index (WPI) score of ≤ 4 and a Symptom Severity Question 2 (SSQ2) score of ≤ 2 at Screening Visit 1
12. Willingness to use an electronic diary on a daily basis in the evening for the screening period and 104-week study duration
13. Negative drug test for amphetamine, buprenorphine, cocaine, methadone, opiates, phencyclidine (PCP), propoxyphene, barbiturates, benzodiazepine, methaqualone, and tricyclic antidepressants, except if any such drugs are clinically indicated and allowed by the protocol, at Screening Visit 1.
14. Subjects with depression or anxiety must be clinically stable for 12 weeks prior to Screening Visit 1 in the opinion of the Investigator and, if on treatment for depression or anxiety, be on 12 weeks of stable therapy
15. Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
16. Subjects must have read and understood the Informed Consent Form (ICF), and must have signed and dated it prior to any study-related procedure being performed
17. Subject's Screening Visit 1 visit must occur while enrollment into the study is open
18. Subject is able to have a Screening Visit 2 qCT image acquired that does not require a re-scan as determined by the central imaging vendor

Exclusion Criteria:

1. Pregnant and breastfeeding women, and women who are not post-menopausal (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) and have a positive or indeterminate pregnancy result at Screening Visit 2 or Day 1
2. Women who are not post-menopausal or permanently surgically sterile, who are sexually active, and who are not willing to use birth control (as outlined in Section 5.3.1) during the study period
3. Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized or who are not using birth control as outlined in Section 5.3.1
4. Body mass index (BMI) \> 35
5. Partial or complete joint replacement in either knee
6. Currently requires:

   1. regular use (in the opinion of the Investigator) of ambulatory assistive devices (e.g., wheelchair, parallel bars, walker, canes, or crutches), or
   2. use of a lower extremity prosthesis, and/or a structural knee brace (i.e., a knee brace that contains hardware)
7. Radiographic disease Stage 0, 1, or 4 in the target knee at Screening Visit 1 according to the Kellgren-Lawrence grading of knee OA as assessed by independent central readers
8. Previous enrollment in a Samumed clinical trial investigating SM04690
9. Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to Screening Visit 1
10. Any bone fracture(s) within 26 weeks prior to Screening Visit 1
11. Any surgery scheduled during the study period. Non-surgical invasive procedures conducted for a diagnostic or therapeutic purpose scheduled during the study period are not prohibited.(refer to section 7.6)
12. Significant and clinically evident misalignment of either knee that would impact subject function, as determined by the Investigator
13. History of malignancy within the last 5 years; however, subjects with prior history of in situ basal or squamous cell skin cancer are eligible if completely excised. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to Screening Visit 1
14. Clinically significant abnormal screening hematology values, blood chemistry values, or urinalysis values as determined by the Investigator
15. Any condition, including laboratory findings not included in the Screening Visit 2 laboratory tests and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
16. Comorbid conditions that could affect study endpoint assessments of the target knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or pseudogout, and fibromyalgia
17. Other conditions that, in the opinion of the Investigator, could affect study endpoint assessments of either knee, including, but not limited to, peripheral neuropathy (e.g., diabetic neuropathy), symptomatic hip osteoarthritis, symptomatic degenerative disc disease, and patellofemoral syndrome
18. History of mania, bipolar disorder, psychotic disorder, schizophrenia, schizoaffective disorder, major depressive disorder, or generalized anxiety disorder
19. Participation in a clinical research trial that included the receipt of an investigational product (IP) or any experimental therapeutic procedure within 26 weeks prior to Screening Visit 1, or planned participation in any such trial
20. Treatment of the target knee with intra-articular glucocorticoids (e.g., methylprednisolone) within 12 weeks prior to Screening Visit 1
21. Any intra-articular injection into the target knee with a therapeutic aim including, but not limited to, viscosupplementation (e.g., hyaluronic acid), platelet-rich plasma (PRP), and stem cell therapies within 24 weeks prior to Screening Visit 1; treatment of the target knee with intra-articular glucocorticoids greater than 12 weeks prior to Screening Visit 1 is allowed
22. Treatment with systemic (oral, intramuscular, or intravenous)glucocorticoids greater than 10 mg prednisone or the equivalent per day within 4 weeks prior to Screening Visit 1
23. Effusion of the target knee clinically requiring aspiration within 12 weeks prior to Screening Visit 1
24. Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 4 weeks prior to Screening Visit 1 (refer to Appendix 1)
25. Any known active infections, including urinary tract infection, upper respiratory tract infection, sinusitis, suspicion of intra-articular infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV) at Day 1
26. Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of centrally acting analgesics (e.g., duloxetine) (refer to Appendix 1) within 12 weeks prior to Screening Visit 1
27. Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of anticonvulsants (not listed in Appendix 1 ) within 12 weeks prior to Screening Visit 1, unless used for seizure or migraine prophylaxis
28. Subjects requiring the usage of opioids \>1x per week within 12 weeks prior to Screening Visit 1
29. Topical local anesthetic agents (gels, creams, or patches such as the Lidoderm patch) used for the treatment of knee OA within 7 days of Screening Visit 1
30. Any chronic condition that has not been well controlled or subjects with a chronic condition who have not maintained a stable therapeutic regimen of a prescription therapy in the opinion of the Investigator. In addition, subjects with an HbA1c \>9 at Screening Visit 2 will be excluded.
31. If on NSAIDs for the treatment of OA pain, subjects who have not maintained a stable regimen in the opinion of the Investigator at Screening Visit 1
32. Any contraindications for performing DXA scans of the hips or spine including but not limited to:

    1. other radiological investigations using contrast media or radionuclides within 7 days of Screening Visit 2
    2. weight that precludes scanning at these sites
33. Subjects who have had a single or bilateral hip replacement
34. Subjects who have a current or pending disability claim, workers' compensation, or litigation(s) that may compromise response to treatment
35. Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at any investigative site, or are directly affiliated with the study at any investigative site
36. Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study, or who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of said employees responsible for the conduct of the study
37. Subject has non-evaluable DXA scans of the hips or spine (i.e., pins, screws, any surgical implant, fracture, or severe degenerative changes in the region of interest), as assessed by the central imaging vendor at the time of screening

Primary outcomes:
measure: Change in BMD from baseline in the treated knee compared to placebo by qCT
timeFrame: Baseline, and Week 52
measure: Safety of SM04690 treatment: adverse events (AEs) and serious adverse events (SAEs)
timeFrame: Baseline through Week 52
Secondary outcomes:
measure: Change from baseline OA pain in the target knee (NRS)
timeFrame: Baseline through Week 52
measure: Change from baseline OA pain in the target knee (WOMAC pain subscore)
timeFrame: Baseline through Week 52
measure: Change from baseline OA function in the target knee (WOMAC physical function subscore)
timeFrame: Baseline through Week 52
measure: Change from baseline OA disease activity
timeFrame: Baseline through Week 52
measure: Change from baseline in medial joint space width (mJSW) of the target knee
timeFrame: Baseline, Weeks 24 and 52
measure: Change in BMD from baseline in the treated knee compared to placebo by qCT
timeFrame: Baseline and Weeks 12, 24 and 36
measure: Difference in the change in BMD from baseline between the treated and untreated knee by qCT
timeFrame: Baseline and Weeks 12, 24, 36 and 52
measure: Change in BMD from baseline by DXA of the spine and hips
timeFrame: Baseline, and Weeks 24 and 52
measure: Change in serum bone biomarker PINP from baseline
timeFrame: Baseline through Week 52
measure: Change in serum bone biomarker β-CTX from baseline
timeFrame: Baseline through Week 52
measure: Change in a serum cartilage biomarker COMP from baseline
timeFrame: Baseline through Week 52
Other outcomes:
measure: Safety of SM04690 treatment: adverse events (AEs) and serious adverse events (SAEs)
timeFrame: Baseline through Week 104
measure: Change in BMD from baseline in the treated knee compared to placebo by qCT
timeFrame: Baseline through Week 104
measure: Difference in the change in BMD from baseline between the treated and untreated knee by qCT
timeFrame: Baseline through Week 104
measure: Change in BMD from baseline by DXA of the spine and hips
timeFrame: Baseline through Week 104
measure: Change in serum bone biomarker PINP from baseline
timeFrame: Baseline through Week 104
measure: Change in serum bone biomarker β-CTX from baseline
timeFrame: Baseline through Week 104
measure: Change in a serum cartilage biomarker COMP from baseline
timeFrame: Baseline through Week 104
measure: Change from baseline OA pain in the target knee (NRS)
timeFrame: Baseline through Week 104
measure: Change from baseline over time for OA pain in the target knee as assessed by WOMAC pain subscore
timeFrame: Baseline through Week 104
measure: Change from baseline over time in mJSW as documented by radiograph of the target knee
timeFrame: Baseline through Week 104
measure: Change from baseline over time for OA function in the target knee as assessed by WOMAC physical function subscore
timeFrame: Baseline through Week 104
measure: Change from baseline over time for OA disease activity
timeFrame: Baseline through Week 104
measure: Number of subjects who required a TKR
timeFrame: Baseline through Week 104
Locations:
city: Phoenix
country: United States
facility: Research Site
state: Arizona
city: Phoenix
country: United States
facility: Research Site
state: Arizona
city: Canoga Park
country: United States
facility: Research Site
state: California
city: Carmichael
country: United States
facility: Research Site
state: California
city: La Mesa
country: United States
facility: Research Site
state: California
city: Edgewater
country: United States
facility: Research Site
state: Florida
city: Miami
country: United States
facility: Research Site
state: Florida
city: Woodstock
country: United States
facility: Research Site
state: Georgia
city: Kansas City
country: United States
facility: Research Site
state: Missouri
city: Albuquerque
country: United States
facility: Research Site
state: New Mexico
city: Cincinnati
country: United States
facility: Research Site
state: Ohio
city: Charleston
country: United States
facility: Research Site
state: South Carolina
city: San Angelo
country: United States
facility: Research Site
state: Texas
Study officials:
affiliation: Biosplice Therapeutics, Inc.
name: Yusuf Yazici, M.D.
role: STUDY_DIRECTOR
References: